This technology utilizes methyl nicotinate, commonly used as a fragrance and skin conditioning agent, as an active ingredient. When applied alongside chemotherapy, it reduces keratinocyte apoptosis and LDH activity, a marker of cellular damage. It is formulated for use in cosmetics, food products, quasi-drugs, and pharmaceuticals.
As the 5-year relative survival rate for cancer patients exceeds 70%, managing side effects has become as critical as treatment efficacy. However, systemic chemotherapy often damages skin cells. These dermatological side effects significantly lower a patient's quality of life, yet there is a lack of safe, long-term management solutions.
This technology is designed to reduce keratinocyte apoptosis caused by chemotherapy agents used for colorectal, breast, and lung cancers, such as 5-fluorouracil, cyclophosphamide, doxorubicin, methotrexate, docetaxel, and cisplatin. As methyl nicotinate is already approved for use as a fragrance and skin conditioning agent, it carries a low risk of side effects with long-term use. It can be applied to hypoallergenic moisturizing creams, ointments, and supplements for cancer patients, supporting skin health throughout the treatment period.
N/A
